NCT01557777View on ClinicalTrials.gov

Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Navitoclax

QD

Trial Locations (15)

3058

Site Reference ID/Investigator# 79201, Coburg

4120

Site Reference ID/Investigator# 78993, Greenslopes

18101

Site Reference ID/Investigator# 77860, Afula

20817

Site Reference ID/Investigator# 74033, Bethesda

29000

Site Reference ID/Investigator# 79205, Khmelnitsky

36024

Site Reference ID/Investigator# 79206, Poltava

76008

Site Reference ID/Investigator# 79203, Ivano-Frankivsk

76100

Site Reference ID/Investigator# 77637, Rehovot

79044

Site Reference ID/Investigator# 79204, Lviv

93454

Site Reference ID/Investigator# 74039, Santa Maria

94523

Site Reference ID/Investigator# 74038, Pleasant Hill

92093-0698

Site Reference ID/Investigator# 74036, La Jolla

90095-7059

Site Reference ID/Investigator# 74035, Los Angeles

80-952

Site Reference ID/Investigator# 77413, Gdansk

03115

Site Reference ID/Investigator# 79202, Kyiv

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01557777 - Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter